A Look At Stepan (SCL) Valuation After Earnings, Goodwill Impairment And Dividend Reaffirmation

Why Stepan’s latest earnings matter for shareholders

Stepan (SCL) just released fourth quarter and full year 2025 results, pairing higher quarterly sales and net income with a goodwill impairment charge and a reaffirmed quarterly cash dividend of $0.395 per share.

This mix of earnings, impairment and dividend news gives you a fresh look at how the chemical producer is balancing reported profitability, balance sheet adjustments and ongoing cash returns to shareholders.

See our latest analysis for Stepan.

Despite the latest quarterly revenue and net income improvement, Stepan’s recent 30 day share price return of a 23.48% decline contrasts with a 7.60% gain over 90 days and a 1 year total shareholder return of a 15.81% decline, hinting that short term momentum has cooled while longer term returns have also been weak.

If earnings and dividend news have you reassessing your portfolio, it could be a useful moment to scan our screener of 20 top founder-led companies for fresh ideas beyond Stepan.

With Stepan shares down over the past year but trading at a discount to analyst targets and some intrinsic estimates, you have to ask yourself: is this weakness a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 36% Undervalued

At a last close of $48.00 against a widely followed fair value of $75.00, the current price sits well below the narrative’s central estimate.

The analysts have a consensus price target of $85.0 for Stepan based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $2.6 billion, earnings will come to $146.1 million, and it would be trading on a PE ratio of 16.5x, assuming you use a discount rate of 7.3%.

Read the complete narrative. Read the complete narrative.

Curious how a mid single digit revenue pace and much stronger profit growth can still justify a higher future earnings multiple than today? The full narrative lays out how that combination supports a fair value materially above the current $48.00 share price, using an 8.48% discount rate and a different assumed P/E than the one in the quote.

Result: Fair Value of $75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh headwinds, such as pressure on free cash flow and margin risk in Surfactants and Polymers, which could challenge this underpriced thesis.

Find out about the key risks to this Stepan narrative.

Another Angle on Stepan’s Valuation

While the narrative fair value of $75 points to Stepan looking undervalued, our DCF model presents an even stronger picture, with the shares trading below an estimated future cash flow value of $134.77. When two methods both lean toward a lower valuation, it raises the question: what risk are you being compensated for taking here?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the mix of optimism and caution here feels familiar, act while the details are fresh and carefully consider the 2 key rewards and 2 important warning signs alongside your own view.

Looking for more investment ideas?

If Stepan sits on your watchlist but you want stronger options, do not wait for the next headline; use this moment to broaden your opportunity set now.

• Target resilience first by checking companies in our solid balance sheet and fundamentals stocks screener (41 results) so you are not relying on hope when markets get choppy.
• Hunt for value by scanning our screener containing 24 high quality undiscovered gems and see which under the radar names already show the kind of fundamentals you want.
• Prioritise peace of mind with our 63 resilient stocks with low risk scores, so you are not wondering what you missed when volatility returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com